Platelet function testing in outpatients after heart transplantation on aspirin therapy

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521699-71-01

Enrollment

100

Registered

2026-05-25

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who have undergone heart transplantation.

Brief summary

Prescence of Aspirin resistance (defined via Multiplate® ASPI test)

Detailed description

Innovance® PFA-200 System Analyzer, VerifyNow®, Age, sex, BMI, active smoker, diabetes mellitus, hypertension, periods of rejection, cardiovascular events/stroke since heart transplantation, C-reactive protein (CRP), neoplasia, ICU stay after heart transplantation, CMV infection, physical activity, HDL-Cholesterol, LDL-Cholesterol, cholesterol, triglyceride

Interventions

DRUGThrombo ASS 100 mg-Filmtabletten

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Prescence of Aspirin resistance (defined via Multiplate® ASPI test)	—

Secondary

Measure	Time frame
Innovance® PFA-200 System Analyzer, VerifyNow®, Age, sex, BMI, active smoker, diabetes mellitus, hypertension, periods of rejection, cardiovascular events/stroke since heart transplantation, C-reactive protein (CRP), neoplasia, ICU stay after heart transplantation, CMV infection, physical activity, HDL-Cholesterol, LDL-Cholesterol, cholesterol, triglyceride	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 26, 2026